Generic Name and Formulations:
Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%; foam.
LEO Pharma Inc.
Indications for ENSTILAR:
Apply to affected areas once daily for up to 4 weeks; discontinue when control is achieved. ≥18yrs: max 60g every 4 days. Do not occlude.
<18yrs: not studied.
Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, or irritation occurs. Do not use on face, axillae, or groin, or if atrophy is present at treatment site. Avoid eyes, sun, UV light (eg, phototherapy). Flammable. Allergic contact dermatitis. Pregnancy (Cat.C). Nursing mothers.
Vit. D3 derivative + topical steroid.
Systemic absorption potentiated by other corticosteroids.
Application site irritation and pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, psoriasis exacerbation.
Foam (60g)—1, 2